Model List of Essential Medicines

Allopurinol

Section	Indications
Supportive medicines ◦ Parenteral > General injections > IV: 500 mg (as sodium) powder for injection ◦ Oral > Solid: 100 mg; 300 mg	Tumour lysis syndrome

Darbepoetin alfa

Section	Indications
Supportive medicines	Therapeutic equivalent to erythropoiesis-stimulating agents for Drug-induced aplastic anaemia

Epoetin alfa

Section	Indications
Supportive medicines	Therapeutic equivalent to erythropoiesis-stimulating agents for Drug-induced aplastic anaemia

Epoetin beta

Section	Indications
Supportive medicines	Therapeutic equivalent to erythropoiesis-stimulating agents for Drug-induced aplastic anaemia

Erythropoiesis-stimulating agents

Section	Indications
Supportive medicines ◦ Parenteral > General injections > unspecified: 2000 IU per mL in vial (single-dose); 3000 IU per mL in vial (single-dose); 4000 IU per mL in vial (single-dose); 10000 IU per mL in vial (single-dose); 40000 IU per mL in vial (single-dose); 20000 IU per mL in vial (multiple-dose); 20000 IU per 2 mL in vial (multiple-dose)	Drug-induced aplastic anaemia

Mesna

Section	Indications
Supportive medicines ◦ Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 2 mL ampoule ◦ Oral > Solid > tablet: 400 mg; 600 mg ◦ Oral > Other: 600 mg ◦ Oral > Solid > tablet: 400 mg ◦ Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule ◦ Oral > Solid: 400 mg; 600 mg	Rhabdomyosarcoma primary site Germ cell tumour of testis Other specified malignant neoplasms of the ovary Osteosarcoma of bone or articular cartilage of unspecified sites Unspecified malignant neoplasms of unspecified sites Ewing sarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of kidney, except renal pelvis Burkitt lymphoma including Burkitt leukaemia

Rasburicase

Section	Indications
Supportive medicines ◦ Parenteral > General injections > IV: 1.5 mg in vial powder and 1 mL solvent for solution; 7.5 mg in vial powder and 5 mL solvent for solution	Tumour lysis syndrome

Zoledronic acid

Section	Indications
Supportive medicines ◦ Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle	Malignant neoplasm metastasis in bone or bone marrow